Telomerase Reverse Transcriptase and miR-34a in diagnosis of non-muscle invasive bladder cancer
Abd El- Razek, W., Awadalla, A., Elbaset, M., Abdel-Megied, A., Mohamed, F., Shokier, A. (2020). Telomerase Reverse Transcriptase and miR-34a in diagnosis of non-muscle invasive bladder cancer. EKB Journal Management System, 16(1), 151-159. doi: 10.21608/blj.2020.146616
Waleed Yousef Abd El- Razek; Amira Awadalla; M.A. Elbaset; Ahmed El-Sayed Abdel-Megied; Faten Zahran Mohamed; Ahmed A. Shokier. "Telomerase Reverse Transcriptase and miR-34a in diagnosis of non-muscle invasive bladder cancer". EKB Journal Management System, 16, 1, 2020, 151-159. doi: 10.21608/blj.2020.146616
Abd El- Razek, W., Awadalla, A., Elbaset, M., Abdel-Megied, A., Mohamed, F., Shokier, A. (2020). 'Telomerase Reverse Transcriptase and miR-34a in diagnosis of non-muscle invasive bladder cancer', EKB Journal Management System, 16(1), pp. 151-159. doi: 10.21608/blj.2020.146616
Abd El- Razek, W., Awadalla, A., Elbaset, M., Abdel-Megied, A., Mohamed, F., Shokier, A. Telomerase Reverse Transcriptase and miR-34a in diagnosis of non-muscle invasive bladder cancer. EKB Journal Management System, 2020; 16(1): 151-159. doi: 10.21608/blj.2020.146616

Telomerase Reverse Transcriptase and miR-34a in diagnosis of non-muscle invasive bladder cancer

Biochemistry Letters
Article 12, Volume 16, Issue 1, 2020, Page 151-159  XML PDF (332.79 K)
Document Type: Original Article
DOI: 10.21608/blj.2020.146616
View on SCiNiTO View on SCiNiTO
Authors
Waleed Yousef Abd El- Razek1; Amira Awadalla2; M.A. Elbaset2; Ahmed El-Sayed Abdel-Megied1; Faten Zahran Mohamed3; Ahmed A. Shokier4
1Department of Chemistry, Faculty of science,Menoufia University, Menoufia, Egypt.
2Center of Excellence for Genome and Cancer Research, Urology and Nephrology
3Department of Chemistry, Faculty of science, Zagazig University, Zagazig, Egypt.
4Center of Excellence for Genome and Cancer Research, Urology and Nephrology.
Abstract
Background: Management of high-risk non-muscle invasive bladder cancer is difficult, as no validated tool exists to predict risk of recurrence. Urine has the potential to contain a variety of molecular markers that may be associated with tumors.
Methods: The study included 3 groups: group 1comprised 100 patients diagnosed with non-muscle invasive bladder cancer (NMIBC). Each of Group 2 included 100 patients with other pathology rather than NMIBC. Group3 comprised 100 healthy persons. Group1 was subdivided into patients with and without recurrence. The patients with recurrent tumors were subclassified into single or multiple recurrences. Urinary markers: TERTand miR-34a were evaluated.
Results: Higher urinary TERT > 3.2 and lower urinary miR34a < 0.85 were detected significantly in NMIBC group compared to controls.
Conclusion: Urinary molecular biomarkers are reliable non-invasive tools for NMIBC detection and prediction of recurrence. Urinary TERT >3.2 and miR34a< 0.85 were significantly higher in patients with NMIBC in comparison with controls. Urinary TERT > 3.2 had the highest overall diagnostic accuracy for bladder cancer detection.
Keywords
Bladder cancer; diagnostic marker; recurrence; qRT-PCR; urine metabolites
Statistics
Article View: 201
PDF Download: 160